What is DA Davidson's Estimate for USNA Q1 Earnings?

USANA Health Sciences, Inc. (NYSE:USNA - Free Report) - Equities research analysts at DA Davidson issued their Q1 2025 earnings per share (EPS) estimates for shares of USANA Health Sciences in a report released on Tuesday, February 25th. DA Davidson analyst C. Xue expects that the company will post earnings of $0.83 per share for the quarter. DA Davidson currently has a "Neutral" rating and a $36.00 target price on the stock. The consensus estimate for USANA Health Sciences' current full-year earnings is $2.45 per share.

A number of other research firms have also issued reports on USNA. Sidoti lowered USANA Health Sciences from a "strong-buy" rating to a "hold" rating in a research note on Tuesday, February 18th. StockNews.com lowered USANA Health Sciences from a "strong-buy" rating to a "buy" rating in a research note on Friday, February 14th.

USANA Health Sciences Stock Performance

USNA stock traded up $0.91 on Wednesday, reaching $29.55. The company had a trading volume of 299,854 shares, compared to its average volume of 166,624. USANA Health Sciences has a 1 year low of $27.71 and a 1 year high of $50.32. The company's fifty day moving average is $33.50 and its 200 day moving average is $36.56. The company has a market cap of $563.22 million, a P/E ratio of 10.44, a PEG ratio of 0.93 and a beta of 0.87.

Remove Ads

USANA Health Sciences (NYSE:USNA - Get Free Report) last posted its earnings results on Tuesday, February 25th. The company reported $0.64 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.49 by $0.15. USANA Health Sciences had a return on equity of 10.64% and a net margin of 6.30%. The firm had revenue of $213.61 million for the quarter, compared to analyst estimates of $208.82 million.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of the business. Pzena Investment Management LLC raised its holdings in USANA Health Sciences by 3.6% in the 4th quarter. Pzena Investment Management LLC now owns 1,087,076 shares of the company's stock valued at $39,015,000 after acquiring an additional 37,466 shares during the last quarter. Dimensional Fund Advisors LP raised its holdings in USANA Health Sciences by 7.7% in the 4th quarter. Dimensional Fund Advisors LP now owns 773,228 shares of the company's stock valued at $27,751,000 after acquiring an additional 55,059 shares during the last quarter. Pacer Advisors Inc. raised its holdings in USANA Health Sciences by 8.8% in the 4th quarter. Pacer Advisors Inc. now owns 592,001 shares of the company's stock valued at $21,247,000 after acquiring an additional 47,745 shares during the last quarter. State Street Corp raised its holdings in USANA Health Sciences by 0.6% in the 3rd quarter. State Street Corp now owns 435,164 shares of the company's stock valued at $16,501,000 after acquiring an additional 2,782 shares during the last quarter. Finally, Geode Capital Management LLC raised its holdings in USANA Health Sciences by 1.6% in the 4th quarter. Geode Capital Management LLC now owns 301,949 shares of the company's stock valued at $10,839,000 after acquiring an additional 4,829 shares during the last quarter. 54.25% of the stock is currently owned by institutional investors and hedge funds.

USANA Health Sciences Company Profile

USANA Health Sciences, Inc develops, manufactures, and sells science-based nutritional, personal care, and skincare products in the Asia Pacific, the Americas, and Europe. The company offers USANA nutritional products that comprise essentials/CellSentials, such as vitamin and mineral supplements that provide a foundation of total body nutrition for various age groups; optimizers consisting of targeted supplements that are designed to meet cardiovascular, skeletal/structural, and digestive health needs; and food that include meal replacement shakes, snack bars, and other related products.